SCHEMBL20203391

SCHEMBL20203391

CC(C)c1ccc(CN2CCN(C[C@H](C)O)CC2)cn1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 2/20 0.47
▸ WDR77 Q9BQA1 2/20 0.47
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ CACNA1G O43497 2/20 0.40
▸ KCNH2 Q12809 2/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ PANK3 Q9H999 2/20 0.39
▸ DRD2 P14416 2/20 0.38
▸ DRD3 P35462 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ IDH1 O75874 1/20 0.37
▸ BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20203394 1.00 PRMT5 (0.47) PRMT5WDR77MEN1KMT2AATM
SCHEMBL18291397 0.84 PRMT5 (0.44) PRMT5WDR77MEN1KMT2AATM
SCHEMBL18291194 0.84 PRMT5 (0.44) PRMT5WDR77MEN1KMT2AATM
SCHEMBL20255232 0.84 PRMT5 (0.44) PRMT5WDR77MEN1KMT2AATM
SCHEMBL17660303 0.84 LMNA (0.50) PRMT5WDR77MEN1KMT2AATM
SCHEMBL20203451 0.84 ALDH1A1 (0.51) PRMT5WDR77MEN1KMT2AATM
SCHEMBL4547913 0.83 HRH3 (0.50) PRMT5WDR77HRH3KDM4EALDH1A1
SCHEMBL12028959 0.83 HRH3 (0.47) PRMT5WDR77MEN1KMT2AATM
SCHEMBL20037541 0.83 PIK3CA (0.48) MEN1KMT2AATMCACNA1GKCNH2
SCHEMBL20038104 0.83 MEN1 (0.43) MEN1KMT2AATMCACNA1GKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 — — US disclosed
EP-3546458-B1 ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER TEIJIN PHARMA LTD (JP) 2021-01-06 — — EP disclosed
EP-3546458-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2019-10-02 — — EP disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 PRMT5 1943/4885WDR77 1134/4885MEN1 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback